Nothing to reconsider. If anyone reads this release this morning and not just the headline, along with reads the previous PRs, slowly, they will quickly realize the company and the "potential partner" have done NOTHING. This is yet another extension of the ability to partner with PTN. They have no definitive agreement in place, nor did PTN get any additional monies to once again sit on its hands while this other specialty pharma does its "due diligence". Read the last three PRs in their entirety and you will quickly realize this is a fluff PR with a fluff headline in an attempt to abate any depreciation. The more I do DD on this company and watch the chart/trading...just makes me more sure of my decisions to exit 85% of my position.
News 
Market Data 
Discover 
AI
